TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Patient has been previously diagnosed with multiple myeloma (MM) based on standard criteria and currently requires treatment because MM has relapsed following a response, according to International Myeloma Working Group (IMWG) criteria.~* Patient had received at least two previous therapies including lenalidomide and proteasome inhibitor and have demonstrated disease progression on therapy or after completion of the last therapy.~* Patients with measurable disease defined as at least one of the following:~  * Serum M protein ≥0.5 g/dL (≥5 g/L);~ * Urine M protein ≥200 mg/24 hours;~ * Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65).~Exclusion criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status \>2.~* Poor bone marrow reserve.~* Poor organ function.~* Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate 80.~* Any serious active disease (including clinically significant infection that is chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the Investigator, could interfere with the safety, the compliance with the study or with the interpretation of the results.~* Any severe underlying medical conditions including presence of laboratory abnormalities, which could impair the ability to participate in the study or the interpretation of its results.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PomdeSAR (Type: EXPERIMENTAL): Part A: Isatuximab (escalating dose) on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression~Part B: Isatuximab 10 mg/kg on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EFFECT OF LOW LEVEL LASER THERAPY VERSUS ELECTROACUPUNCTURE ON POSTNATAL SCANTY MILK SECRETION

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Their age ranged between 20 and 35 years old~* 25 to 30 kg/m² body mass index (BMI).~* They attended the breast feeding clinic complaining from insufficiency of lactation within the 1st month after normal vaginal delivery and they were using mixed feeding (Both breast and bottle feeding at least 3 bottles per day and not more than 6 bottles).~* They had approximately the same nutrition as well as, education level~Exclusion Criteria:~* lactating mothers who suffered from post-partum hemorrhage~* cardio respiratory disease~* diabetes mellitus~* breast cancer~* previous surgeries in the chest, breast or the surrounding area~* anemia~* those who had any causes that hindering their normal breast feeding as (retraced, cracked, inflamed or inverted nipples)~* Women receiving contraceptive pills,~* conditions related to the infant that affect the lactation process were excluded such as congenital conditions of infant mouth: tongue tie, cleft of the soft palate and congenital heart disease of the infant

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: ACTIVE_COMPARATOR): 10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
- Laser group (Type: ACTIVE_COMPARATOR): The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)
- Electro acupuncture group (Type: ACTIVE_COMPARATOR): faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with a body mass index \>35 who have undergone cesarean delivery in the last 12 hours who will receive thromboprophylaxis with enoxaparin~* Subjects who consent to the study.~Exclusion Criteria:~* Women with a previous history of deep venous thrombosis or pulmonary embolism~* Women who are currently receiving another form of low molecular weight heparin or unfractionated heparin.~* Women who are receiving other concomitant anticoagulant medications, such as warfarin, lepirudin, or argatroban.~* Subjects who are unable or unwilling to give informed consent.~* Women who, in the judgment of the investigators, would not be in the best interest of the patient to participate in the study.~* Allergy to enoxaparin.~* Women with renal impairment~* Women with contraindications to Lovenox treatment such as women with active bleeding or thrombocytopenia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Enoxaparin Once Daily (Type: ACTIVE_COMPARATOR): This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
- Enoxaparin Twice Daily (Type: ACTIVE_COMPARATOR): This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known coronary artery disease who presented with and ACS and underwent PCI.~* Age between 18 and 74 years old.~* On therapy with low-dose aspirin (81 mg) and prasugrel 10 mg/daily for at least 14 days as per standard of care~Exclusion criteria:~* History of stroke, transient ischemic attack (TIA) or intracranial bleeding.~* Known allergies to ticagrelor.~* Weight \< 60 Kg~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).~* Treatment with IIb/IIIa glycoprotein inhibitors in the last 7 days.~* Blood dyscrasia or bleeding diathesis.~* Platelet count \<80x106/mL.~* Hemoglobin \<10 g/dL.~* Active bleeding.~* Hemodynamic instability.~* Creatinine Clearance \<30 mL/minute.~* Known severe hepatic dysfunction.~* Patients with sick sinus syndrome (SSS) or high degree atrio-ventricular block without pacemaker protection.~* Current treatment with drugs interfering with cytochrom P450 3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin.~* Pregnant females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 180mg (Type: EXPERIMENTAL): Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
- Ticagrelor 90mg (Type: EXPERIMENTAL): Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
- Prasugrel 10mg (Type: ACTIVE_COMPARATOR): Patients already on prasugrel, will maintain prasugrel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized at Vanderbilt University Medical Center~* Medicare-eligible~* Discharged from VUMC to a post acute care facility~* Has polypharmacy as defined by \> 5 medications~* Able to self-consent or has a proxy (surrogate)~* Speaks English (due to interview-based assessments)~* Primary home residence within one of 9 surrounding counties (due to home visit during follow-up phase)~Exclusion Criteria:~* Resides in long-term care~* Is currently on hospice or otherwise has a limited life expectancy (\< 6 months).~* Enrolled in a clinical drug trial~* Has Stage IV Cancer Diagnosis~* Incarcerated or homeless~* Unable to self-consent and does not have a surrogate

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shed-Meds: A Patient-Centered Deprescribing Intervention (Type: EXPERIMENTAL): Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
- Control Group (Type: NO_INTERVENTION): Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria include:~* Participants with IDA and in whom IV iron treatment is indicated and defined as:~  * Participants with documented hemoglobin \<12.0 g per deciliter (dL) for females and \<14.0 g/dL for males within 60 days of dosing And~ * Participants with documented transferrin saturation (TSAT) ≤20% or Ferritin ≤100 nanograms (ng) per mL within 60 days of dosing~* Documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate (as per oral iron history questionnaire)~* All participants (male and female) of childbearing potential who are sexually active who agree to routinely use adequate contraception from randomization throughout the duration of the study~Key Exclusion Criteria include:~* Known hypersensitivity reaction to any component of ferumoxytol or FCM~* History of allergy to an IV iron~* History of multiple drug allergies~* Participants with dialysis-dependent chronic kidney disease~* Hemoglobin ≤7.0 g/dL~* Female participants who are pregnant, intend to become pregnant, are breastfeeding, have a positive serum/urine pregnancy test or not willing to use effective contraceptive precautions during the study (including females of childbearing potential who are partners of male participants)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: EXPERIMENTAL): Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter \[mL\]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
- FCM (Type: ACTIVE_COMPARATOR): Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mini-Dose Glucagon to Treat Fasting-induced Hypoglycemia During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of T1DM using daily insulin~2. 18.0 to \< 65.0 years of age with body mass index 20.0 to \<35.0 kg/m2.~3. Having diabetes for ≥2.0 years~4. HbA1c \<8.5%~5. Has a smart phone with access to the internet and welling to upload data during the study period.~6. Welling to wear a devise such as continuous glucose monitor ≥6 days/week.~7. Females, not currently known to be pregnant~8. In good general health as evaluated by investigator based on available clinical data~9. Willing to comply to the protocol requirements for the duration of the study~Exclusion Criteria:~1. Any history of more than one severe hypoglycemic episode (need assistance by third party) in the past 12 months~2. Any history of more than one episode of diabetic ketoacidosis in the past 12 months~3. Female pregnant or planning to get pregnant.~4. Use of any of the following medications: oral hypoglycemic agents, systemic corticosteroids or beta-blocker, theophylline, beta-adrenergic agonists, 1st generation anticholinergic drugs.~5. History of hypersensitivity to glucagon or severe hypersensitivity reactions (such as angioedema) to any other medications~6. History of uncontrolled hypertension (systolic BP \>160 mmHg or diastolic BP \>100 mmHg)~7. History of seizure disorder.~8. Presence of any of conditions based on judgment of the investigator that could affect or interfere with the response, absorption, metabolism or execration of glucagon.~9. Currently following any kind of weight-loss diet~10. Currently participation in another clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Glucagon injection (Type: EXPERIMENTAL): Dilute Glucagon (1 mg/ml)
- Glucose tablets (Type: ACTIVE_COMPARATOR): Dextrose glucose tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion criteria:~* Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.~* Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome of (9:22) translocations~Key Exclusion criteria:~* Previously documented T315I mutation~* Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except for no more than 2 weeks in duration of imatinib~* Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide~* Impaired cardiac function.~* Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).~* Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)~* Currently receiving treatment with any medications that have the potential to prolong the QT interval.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nilotinib 300mg bid (investigating arm) (Type: EXPERIMENTAL): None
- Nilotinb 400 mg bid (investigating arm) (Type: EXPERIMENTAL): None
- imatinib 400mg QD (control arm) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Diagnosis of primary systemic amyloidosis~PATIENT CHARACTERISTICS:~* Not pregnant~* Negative pregnancy test~* Able to tolerate an anticoagulation regimen (e.g., 325 mg of aspirin per day, therapeutic warfarin, or low molecular weight heparin)~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~  * Permanent or stable side effects/changes allowed~* Prior chemotherapy, thalidomide, lenalidomide, or steroids for amyloidosis allowed~* More than 4 weeks since prior and no other concurrent cytotoxic chemotherapy or radiotherapy~Exclusion Criteria:~* No secondary or familial amyloidosis~* No multiple myeloma (≥ 30% plasma cells in bone marrow biopsy or lytic bone lesions)~* No prior cumulative doses of oral melphalan \> 200 mg~* No more than one prior course of high-dose melphalan with stem cell transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melphalan Revlimid and Dexamethasone (Type: EXPERIMENTAL): Melphalan Lenalidomide Dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Histologically proven cutaneous lupus erythematosus with or without associated systemic disease~* Presence of at least a grade II erythema as assessed by the validated modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Cutaneous lesions involving more than 18% of the body surface calculated according to the rule of the nines, or history of severe side effects or lack of efficacy following thalidomide therapy, in cutaneous lupus disease refractory to conventional treatment with antimalarials and topical steroids.~* No pregnancy or wish to become pregnant during the study period.~Exclusion Criteria:~* Pregnancy, breastfeeding or the use of not adequate contraception.~* Severe thrombocytopenia (\<30x10E9 cells/L) or leucopoenia (\<1500x10E9), known at least 30 days prior to the onset of the study,~* Previous history of arterial/venous thrombosis,~* Presence of antiphospholipid antibodies~* Presence of moderate-severe renal impairment (FG \<30 ml/min)~* Progressive renal disease.~* Lack of written informed consent prior to participation in the study.~* Presence of a concomitant systemic flare that may require other systemic treatments for its control~* Any psychiatric o social disease that may interfere with the study and follow-up~* HIV, B or C hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lenalidomide Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* best corrected visual acuity in both eyes of at least +0.7~* six-month documented history of dry eye disease~* at least mild severity in 2 of the 4 dry eye symptoms~* unanesthetized Schirmer score of less than or equal to 7mm~* corneal fluorescein staining of greater than or equal to 4 (out of 15)~Exclusion Criteria:~* nasally stimulated Schirmer score of less than 3mm in subjects with an initial Schirmer score of 0mm~* ongoing contact lens wear~* current topical ophthalmic medication use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete